DNA methylation, Methylation, Cancer research, CpG site and Cancer are his primary areas of study. His studies in DNA methylation integrate themes in fields like Carcinogenesis, Molecular biology and Epigenetics. The Methylation study combines topics in areas such as MLH1, Immunology, Promoter, Internal medicine and DNA repair.
His Internal medicine research is multidisciplinary, incorporating perspectives in Endocrinology, Oncology and Decitabine. His Cancer research research is multidisciplinary, relying on both Pathology, Tumor suppressor gene, Regulation of gene expression, Gene silencing and Colorectal cancer. Jean Pierre J. Issa interconnects CpG Island Methylator Phenotype and Microsatellite instability in the investigation of issues within CpG site.
His main research concerns DNA methylation, Methylation, Cancer research, Epigenetics and CpG site. The various areas that he examines in his DNA methylation study include Carcinogenesis, Cancer and Molecular biology. His Methylation study integrates concerns from other disciplines, such as CpG Island Methylator Phenotype, Promoter, Internal medicine, Leukemia and Colorectal cancer.
His Internal medicine research focuses on Hypomethylating agent and how it relates to Oncology. The concepts of his Cancer research study are interwoven with issues in Tumor suppressor gene, Immunology, Decitabine and Pathology. His Epigenetics research incorporates themes from Chromatin, Epigenomics, Histone and Epigenetic therapy.
Jean Pierre J. Issa spends much of his time researching DNA methylation, Epigenetics, Cancer research, Methylation and Internal medicine. Jean Pierre J. Issa is involved in the study of DNA methylation that focuses on CpG site in particular. Jean Pierre J. Issa combines subjects such as Chromatin, Epigenetic therapy and Epigenome with his study of Epigenetics.
His study on Cancer research also encompasses disciplines like
Jean Pierre J. Issa mostly deals with DNA methylation, Epigenetics, Cancer research, Cancer and CpG site. His research integrates issues of Molecular biology and Methylation, DNA in his study of DNA methylation. His Methylation study improves the overall literature in Gene.
His Epigenetics study incorporates themes from Epigenomics, Epigenesis, Bioinformatics and Epigenome. His Cancer research research includes elements of DNA Methyltransferase Inhibitor, EZH2, Histone methylation and Decitabine. His Decitabine research includes themes of Internal medicine and Pharmacology.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia
Timothy J. Ley;Christopher Miller;Li Ding;Benjamin J. Raphael.
The New England Journal of Medicine (2013)
CpG island methylator phenotype in colorectal cancer.
Minoru Toyota;Nita Ahuja;Mutsumi Ohe-Toyota;James G. Herman.
Proceedings of the National Academy of Sciences of the United States of America (1999)
ALTERATIONS IN DNA METHYLATION : A FUNDAMENTAL ASPECT OF NEOPLASIA
Stephen B. Baylin;James G. Herman;Jeremy R. Graff;Paula M. Vertino.
Advances in Cancer Research (1998)
Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma
James G. Herman;Asad Umar;Kornelia Polyak;Jeremy R. Graff.
Proceedings of the National Academy of Sciences of the United States of America (1998)
Inactivation of the CDKN2/p16/MTS1 Gene Is Frequently Associated with Aberrant DNA Methylation in All Common Human Cancers
James G. Herman;Adrian Merlo;Li Mao;Rena G. Lapidus.
Cancer Research (1995)
Methylation of the oestrogen receptor CpG island links ageing and neoplasia in human colon.
Jean Pierre J. Issa;Yvonne L. Ottaviano;Paul Celano;Stanley R. Hamilton.
Nature Genetics (1994)
CpG island methylator phenotype in cancer
Jean-Pierre Issa.
Nature Reviews Cancer (2004)
Dnmt3a is essential for hematopoietic stem cell differentiation.
Grant A. Challen;Deqiang Sun;Mira Jeong;Min Luo.
Nature Genetics (2012)
A simple method for estimating global DNA methylation using bisulfite PCR of repetitive DNA elements
Allen S. Yang;Marcos R.H. Estécio;Ketan Doshi;Yutaka Kondo.
Nucleic Acids Research (2004)
Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies.
Jean Pierre J. Issa;Guillermo Garcia-Manero;Francis J. Giles;Rajan Mannari.
Blood (2004)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:
The University of Texas MD Anderson Cancer Center
The University of Texas MD Anderson Cancer Center
Johns Hopkins University
The University of Texas MD Anderson Cancer Center
Augusta University
University of California, Irvine
Sapporo Medical University
The University of Texas MD Anderson Cancer Center
The University of Texas MD Anderson Cancer Center
The University of Texas MD Anderson Cancer Center
Office National d'Études et de Recherches Aérospatiales
Kyushu University
Ghent University
Chalmers University of Technology
University College London
University of Tartu
University of Valencia
University of Veterinary Medicine Vienna
Duke University
National Institutes of Health
Lawrence Berkeley National Laboratory
Energy Research Centre of the Netherlands
University of Rhode Island
National Oceanic and Atmospheric Administration
University of California, San Diego
Flinders University